Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny

Theodore S Nowicki1,2,3,4,5,6, Nataly Naser Al Deen7, Cole W Peters8

  • 1Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA. tnowicki@mednet.ucla.edu.

PubMed
Summary

This study introduces a novel tandem cell therapy using engineered T cells and hematopoietic stem cells (HSCs) for solid tumors. The approach provides a self-renewing source of cancer-fighting T cells, improving long-term efficacy.